Updates
** Shares of drugmaker Eli Lilly LLY.N fall 8.6% to $821.62
** CVS Health CVS.N says it plans to drop LLY's obesity drug Zepbound from the list of medicines it covers for reimbursement
** CVS says it would drop coverage from July 1, but keep reimbursing for rival GLP-1 weight-loss drug Wegovy after negotiating a more favorable price from Novo Nordisk NOVOb.CO
** Q1 sales of Zepbound of $2.31 billion came in slightly below analysts' estimates of $2.33 billion, as per data compiled by LSEG
** Co also cuts annual adj. profit forecast to between $20.78 per share and $22.28 per share from $22.50 per share to $24 per share previously
** Including session's moves, LLY up 7.9% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.